Screener / SEC EDGAR /CIK 0001232524 /10-K filed Feb 24, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Jazz Pharmaceuticals plc JAZZ

Compare with peers Embed
What it said it expected, against what it reported

4 targets with a reported result

Releases of the last 3 years
Above the range 2 above the last range given
Within the range 2 of 4 range targets
Below the range 0 below the last range given

The numbers JAZZ said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Revenue
Fiscal 2026
Given $4.25B to $4.50B release Feb 24, 2026
Kept $4.25B to $4.50B release May 5, 2026
Raised $4.60B to $4.75B release Aug 3, 2026
Raised $4.78B to $4.85B release Nov 2, 2026
– Not reported yet
The company's words
– Expect 2026 total revenues of $4.25 to $4.50 billion – DUBLIN, February 24, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2025 and provided financial guidance for 2026. release Feb 24, 2026
(In millions) Guidance … Total Revenues $4,250 - $4,500 release May 5, 2026
Following strong 1H26 commercial execution, the company raised its 2026 revenue guidance range to $4.60 - $4.75 billion, reflecting anticipated double- digit YoY revenue growth from both Xywav and the combined epilepsy and oncology franchises. release Aug 3, 2026
Raised 2026 total revenue guidance to a range of $4.775 - $4.85 billion. release Nov 2, 2026
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $4.15B to $4.40B release Feb 25, 2025
Kept $4.15B to $4.40B release May 6, 2025
Lowered $4.15B to $4.30B release Aug 5, 2025
Narrowed $4.17B to $4.28B release Nov 5, 2025
$4.27B
10-K filed 2026-02-24
Within the range
The company's words
Top- and bottom-line growth expected in 2025; 2025 total revenue guidance of $4.15 - $4.40 billion, representing 5% growth at the midpoint. release Feb 25, 2025
We are affirming our 2025 total revenue guidance range of $4.15 - $4.40 billion, reflecting our confidence in our commercial portfolio delivering top-line growth this year,” said Bruce Cozadd, chairman and chief executive officer, Jazz Pharmaceuticals. release May 6, 2025
2025 Financial Guidance … Updating total revenue range to $4.15 - $4.30 billion representing 4% growth at the midpoint. release Aug 5, 2025
Narrowed 2025 total revenue guidance range to $4.175 - $4.275 billion from $4.150 - $4.300 billion. release Nov 5, 2025
Net income
Fiscal 2024 (ended Dec 31, 2024)
Given $385.00M to $530.00M release Jul 31, 2024
$560.12M
10-K filed 2025-02-26
Above the range
The company's words
2024 Financial Guidance: … Affirming GAAP net income guidance of $385 to $530 million and non-GAAP adjusted net income guidance of $1.275 to $1.350 billion. 1 release Jul 31, 2024
Net income (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $1.27B to $1.35B release Jul 31, 2024
– No standard number
The company's words
2024 Financial Guidance: … Affirming GAAP net income guidance of $385 to $530 million and non-GAAP adjusted net income guidance of $1.275 to $1.350 billion. 1 release Jul 31, 2024
Diluted EPS (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $19.20 to $20.30 release Jul 31, 2024
Raised $19.50 to $20.60 release Nov 6, 2024
– No standard number
The company's words
2024 Financial Guidance: … Raising GAAP EPS guidance range by approximately $1.00 to $6.00 to $8.00 and non-GAAP EPS guidance to $19.20 to $20.30. 1 release Jul 31, 2024
2024 Financial Guidance: … Raising GAAP EPS guidance range to $6.70 to $8.50 and non-GAAP EPS guidance range to $19.50 to $20.60. 2 release Nov 6, 2024
Diluted EPS
Fiscal 2024 (ended Dec 31, 2024)
Given $0.65 to $0.75 release Jul 31, 2024
Raised $6.70 to $8.50 release Nov 6, 2024
$8.65
10-K filed 2025-02-26
Above the range
The company's words
This election is expected to increase our full-year net income per diluted share guidance by $0.10 to $0.20 per share, on a GAAP basis, and $0.65 to $0.75 per share, on a non-GAAP adjusted basis, as a result of an estimated decrease in the weighted-average outstanding shares of 2.9 million shares. release Jul 31, 2024
2024 Financial Guidance: … Raising GAAP EPS guidance range to $6.70 to $8.50 and non-GAAP EPS guidance range to $19.50 to $20.60. 2 release Nov 6, 2024
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $4.00B to $4.20B release Feb 28, 2024
Kept $4.00B to $4.20B release May 1, 2024
Lowered $4.00B to $4.10B release Jul 31, 2024
Kept $4.00B to $4.10B release Nov 6, 2024
$4.07B
10-K filed 2025-02-26
Within the range
The company's words
2024 total revenue guidance of $4.0 to $4.2 billion, 7% top-line growth at the mid-point. release Feb 28, 2024
Affirmed 2024 total revenue guidance of $4.0 to $4.2 billion. 1 release May 1, 2024
– Narrowing 2024 total revenue guidance to $4.0 to $4.1 billion – release Jul 31, 2024
– 2024 total revenue guidance affirmed at $4.0 to $4.1 billion – release Nov 6, 2024
1 target far from the company's reported total, so not compared (usually a target for one product, segment or definition)
  • Diluted EPS, Fiscal 2025 (ended Dec 31, 2025): said $4.80 to $5.60, reported $-5.84. The company's words

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (15 releases since 2024-01-08), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/JAZZ/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.